BW

Puma Biotechnology Releases Updated Corporate Presentation

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and President, Alan H. Auerbach, will refer to in meetings beginning Monday, January 9, 2023. The updated presentation includes, among other things, the Company’s preliminary estimate that it…
Leer más...

Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics

Investment will double capacity to produce active pharmaceutical ingredients used in therapeutics for a broad range of diseases SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of the $1…
Leer más...

Rockland Trust Company and Independent Bank Corp. Appoint Jeffrey J. Tengel as Chief Executive Officer

Accomplished commercial banker Tengel to take helm as Oddleifson retires after two decades as CEO ROCKLAND, Mass.--(BUSINESS WIRE)--Rockland Trust Company and its bank holding company parent Independent Bank Corp. (NASDAQ Global Select Market: INDB) today announced the appointment of Jeffrey J. Tengel as the successor to current Chief Executive Officer,…
Leer más...

Griffon Corporation Announces Entry Into Cooperation Agreement with Voss Capital

NEW YORK--(BUSINESS WIRE)--Griffon Corporation (“Griffon” or the “Company”) (NYSE:GFF) announced today that it has entered into a cooperation agreement (the “Cooperation Agreement”) with Voss Capital (“Voss”), which owns approximately 6.0% of the Company’s outstanding common stock, including the appointment of Travis W. Cocke, Chief Investment Officer of Voss, to Griffon’s…
Leer más...

FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

FSD Pharma Inc Announces Three Key Additions to Scientific and Clinical Expert Committee FSD Pharma Inc Announces It Is Investigating Other Products Addressing Acute Medical Needs Due to Substances of Abuse Such as Alcohol TORONTO--(BUSINESS WIRE)--$HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”),…
Leer más...